Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm caused by a reciprocal
translocation [t (9; 22)(q34; q11. 2)] that leads to the fusion of ABL1 gene sequences (9q34) …

Molecular monitoring in chronic myeloid leukemia (CML) is a powerful tool to document
treatment responses and predict relapse. Nonetheless, the proliferation of clinical trials and …

Bosutinib is approved for newly diagnosed Philadelphia chromosome-positive (Ph+) chronic
phase (CP) chronic myeloid leukemia (CML) and for Ph+ CP, accelerated (AP), or blast (BP) …

Context: Medullary thyroid carcinoma (MTC) metastasizes early in its clinical course. No
effective systemic therapy is available. Generally (somatic or germline), mutations in the …

Abstract Development of kinase domain mutations is a major drug-resistance mechanism for
tyrosine kinase inhibitors (TKIs) in cancer therapy. A particularly challenging example is …

β-Lactam compounds play a key role in medicinal chemistry, specifically as the most
important class of antibiotics. Here, we report a novel one-step approach for the synthesis of …

Dendritic cells are the most powerful antigen-presenting cells playing a decisive role for the
initiation and maintenance of primary immune responses. However, signaling pathways …

Natural killer (NK) cells are expanded in chronic myeloid leukemia (CML) patients on
tyrosine kinase inhibitors (TKI) and exert cytotoxicity. The inherited repertoire of killer …

Abstract Treatment of sclerodermatous chronic GVHD (cGVHD) remains disappointing.
Imatinib mesylate enables selective, dual inhibition of the transforming growth factor β …

The introduction of oral tyrosine kinase inhibitors (TKIs) has dramatically improved outcomes
in chronic myeloid leukemia (CML) patients. However, treatment success is directly related …